USE OF AN IN VIVO MODEL SYSTEM TO INVESTIGATE NIDDM

我们一直在研究体内模型系统的使用， 用于非胰岛素需要型糖尿病的潜在药物 （NIDDM）。 B医生。马里兰州大学的汉森有一口特别的井 描述了这种疾病的恒河猴模型。 因此，我们给了两个 肽，GIP和GLP，都已知在其他动物中具有促胰岛素作用， 系统，这些猴子。 我们已经确定了 最大的促胰岛素作用。 我们发现即使是NIDDM猴子 如果给予足够的这些药物，会产生促胰岛素作用。 我们展示 GLP胰岛素释放所需的葡萄糖阈值。 进一步 计划使用这些肽的组合进行研究。

We have been investigating the use of an in vivo model system, to study potential agents for use in non-insulin requiring diabetes mellitus (NIDDM). Dr. B. Hansen, University of Maryland, has an extraordinary well characterized rhesus monkey model of this disease. We therefore gave two peptides, GIP and GLP, both known to have insulinotropic effects in other systems, to these monkeys. We ascertained the dose required to give half maximum insulinotropic effects. We showed that even the NIDDM monkeys can get an insulinotropic effect if given enough of these agents. We showed the glucose threshold required for insulin release by GLP. Further studies are planned using combinations of these peptides.